🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this trial is to compare two different treatments for fit pa...
Status
Unknown
Location
Netherlands Cancer Institute
Start Date
2008-12
Trial ID
NCT00774319
Intervention prospective monocentric one arm study on the use of neoadjuvan...
Status
Recruiting
Location
AOU Careggi
Start Date
2022-07-19
Trial ID
NCT05761054
Treatments Being Tested
This phase II trial studies the side effects and how well giving paclitaxel...
Status
Completed
Location
Nebraska Medicine-Bellevue
Start Date
2012-12-07
Trial ID
NCT01750073
Determine the doses and schedule appropriate for phase 2 study of sorafenib...
Status
Completed
Location
Virginia Commonwealth University/Massey Cancer Center
Start Date
2015-01-29
Trial ID
NCT02349867
This phase II trial tests the effect of giving pembrolizumab in combination...
Status
Recruiting
Location
University of Alabama at Birmingham Cancer Center
Start Date
2025-11-25
Trial ID
NCT07061964
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth...
Status
Completed
Location
M.D. Anderson Cancer Center at University of Texas
Start Date
2006-04
Trial ID
NCT00301028
Treatments Being Tested
Preoperative radiation with single agent chemotherapy as sensitizer is the ...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2019-08
Trial ID
NCT03975049
Treatments Being Tested
This phase II trial studies the side effects and how well pembrolizumab wor...
Status
Active Not Recruiting
Location
Mayo Clinic Hospital in Arizona
Start Date
2018-01-15
Trial ID
NCT03197506
This research trial is studying a combination of neoadjuvant radiotherapy (...
Status
Active Not Recruiting
Location
Sibley Memorial Hospital
Start Date
2020-12-16
Trial ID
NCT04443348
Phase II trial of Neoadjuvant \[FEC100\]/Cisplatin-Docetaxel ± Trastuzumab ...
Status
Completed
Location
Multiple Locations
Start Date
2007-06
Trial ID
NCT00535509